United States Biotechnology & Medical Research

MacroGenics Inc (MGNX)

Track

Over the past 90 days, MacroGenics Inc. recorded two insider transactions, both involving proposed sales totaling approximately $206,464. These sales were executed by a former director and a former officer. The company's stock has seen a 26.9% price increase over the same period, following a recent earnings report that missed EPS expectations by 5.94%.
Ticker: MGNX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for MacroGenics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 3 Aug 2026
Value US$4,166,290.75 | Price 191.59 | Shares 96,427
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-03 2026-08-03 PrS Proposed sale
Jay Siegel

Former Director

Non-Executive Director
96,427
191.59
US$4,166,291 		96,427 191.59 US$4,166,291
2026-07-13 2026-07-13 PrS Proposed sale
Thomas Spitznagel

Former Officer

Officer
88,843
232.97
US$3,644,635 		88,843 232.97 US$3,644,635
2025-08-21 2025-08-20 B Purchase
3.7
HEIDEN WILLIAM K
Non-Executive Director
92,226 -49.4%
412.12
US$2,071,369 		92,226 -49.4% 412.12 US$2,071,369
2025-08-21 2025-08-19 B Purchase
3.7
HEIDEN WILLIAM K
Non-Executive Director
50,500 +459.1%
1.52
US$76,760 		50,500 +459.1% 1.52 US$76,760
2025-02-19 2025-02-15 S Sale
3.3
Smith Beth Ann

VP, Controller & Treasurer

Officer
423 -4.2%
2.56
US$1,083 		423 -4.2% 2.56 US$1,083
2024-04-08 2024-04-04 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
3,165 -100.0%
18.22
US$57,666 		3,165 -100.0% 18.22 US$57,666
2024-04-08 2024-04-04 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
5,351 -62.8%
17.74
US$94,927 		5,351 -62.8% 17.74 US$94,927
2024-04-08 2024-04-04 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
232 -2.7%
16.38
US$3,800 		232 -2.7% 16.38 US$3,800
2024-04-08 2024-04-04 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
147 -1.7%
15.51
US$2,280 		147 -1.7% 15.51 US$2,280
2024-04-08 2024-04-04 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
42,500 -82.7%
15.07
US$640,475 		42,500 -82.7% 15.07 US$640,475
2024-04-04 2024-04-04 PrS Proposed sale
Peters Jeffrey Stuart

Officer

Officer
51,395
15.54
US$798,787 		51,395 15.54 US$798,787
2024-03-08 2024-03-06 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
19,625 -68.8%
21.50
US$421,938 		19,625 -68.8% 21.50 US$421,938
2024-03-06 2024-03-06 PrS Proposed sale
Peters Jeffrey Stuart

Officer

Officer
19,625
20.99
US$411,880 		19,625 20.99 US$411,880
2024-03-06 2024-03-04 PlS Planned sale
Spitznagel Thomas

Sr VP, Technical Ops

Officer
10,000 -54.6%
20.00
US$200,000 		10,000 -54.6% 20.00 US$200,000
2024-03-06 2024-03-04 PlS Planned sale
3.3
Karrels James

SVP, CFO and Secretary

Officer
30,000 -14.9%
20.50
US$615,000 		30,000 -14.9% 20.50 US$615,000
2024-03-06 2024-03-04 PlS Planned sale
Risser Eric Blasius

Chief Operating Officer

Officer
26,159 -40.2%
19.63
US$513,501 		26,159 -40.2% 19.63 US$513,501
2024-03-06 2024-03-04 PlS Planned sale
Risser Eric Blasius

Chief Operating Officer

Officer
15,000 -18.7%
20.00
US$300,000 		15,000 -18.7% 20.00 US$300,000
2024-03-04 2024-03-04 PrS Proposed sale
Spitznagel Thomas

Officer

Officer
10,000
20.00
US$199,985 		10,000 20.00 US$199,985
2024-03-04 2024-03-04 PrS Proposed sale
Risser Eric Blasius

Officer

Officer
41,159
19.82
US$815,612 		41,159 19.82 US$815,612
2024-03-04 2024-03-04 PrS Proposed sale
3.3
Karrels James

Officer

Officer
30,000
20.50
US$615,000 		30,000 20.50 US$615,000
2024-02-28 2024-02-26 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
16,124 -64.4%
17.22
US$277,655 		16,124 -64.4% 17.22 US$277,655
2024-02-26 2024-02-26 PrS Proposed sale
Peters Jeffrey Stuart

Officer

Officer
16,124
17.11
US$275,818 		16,124 17.11 US$275,818
2024-02-07 2024-02-07 PrS Proposed sale
Bonvini Ezio

Officer

Officer
3,334
18.00
US$59,998 		3,334 18.00 US$59,998
2024-02-07 2024-02-07 PlS Planned sale
Bonvini Ezio

Sr VP, Research & CSO

Officer
3,334 -4.5%
18.00
US$60,012 		3,334 -4.5% 18.00 US$60,012
2024-02-07 2024-02-05 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
21,875 -100.0%
16.50
US$360,938 		21,875 -100.0% 16.50 US$360,938
2024-02-07 2024-02-05 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
54,376 -71.3%
16.50
US$897,204 		54,376 -71.3% 16.50 US$897,204
2024-02-05 2024-02-05 PrS Proposed sale
Peters Jeffrey Stuart

Officer

Officer
76,251
16.50
US$1,258,054 		76,251 16.50 US$1,258,054
2024-02-02 2024-02-01 PlS Planned sale
Bonvini Ezio

Sr VP, Research & CSO

Officer
13,316 -15.1%
15.00
US$199,740 		13,316 -15.1% 15.00 US$199,740
2024-02-01 2024-02-01 PrS Proposed sale
Bonvini Ezio

Officer

Officer
13,316
15.00
US$199,725 		13,316 15.00 US$199,725
2024-01-22 2024-01-19 PlS Planned sale
Bonvini Ezio

Sr VP, Research & CSO

Officer
13,316 -13.1%
12.00
US$159,792 		13,316 -13.1% 12.00 US$159,792
2024-01-19 2024-01-19 PrS Proposed sale
Bonvini Ezio

Officer

Officer
13,316
12.00
US$159,777 		13,316 12.00 US$159,777
2023-12-21 2023-12-20 PlS Planned sale
Bonvini Ezio

Sr VP, Research & CSO

Officer
18,880 -15.7%
10.08
US$190,310 		18,880 -15.7% 10.08 US$190,310
2023-12-20 2023-12-20 PrS Proposed sale
Bonvini Ezio

Officer

Officer
18,880
10.08
US$190,295 		18,880 10.08 US$190,295
2023-10-04 2023-10-02 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
150,000 +1.5%
4.46
US$669,585 		150,000 +1.5% 4.46 US$669,585
2023-09-11 2023-09-07 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
200,000 +2.1%
5.26
US$1,052,840 		200,000 +2.1% 5.26 US$1,052,840
2023-09-01 2023-08-30 B Purchase
2.5
HURWITZ EDWARD
Non-Executive Director
15,000 +83.0%
4.91
US$73,650 		15,000 +83.0% 4.91 US$73,650
2023-03-14 2023-03-10 PlS Planned sale
Peters Jeffrey Stuart

Senior VP and General Counsel

Officer
5,372 -100.0%
6.03
US$32,393 		5,372 -100.0% 6.03 US$32,393
2023-02-16 2023-02-14 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
500,000 +5.5%
5.07
US$2,532,600 		500,000 +5.5% 5.07 US$2,532,600
2023-01-23 2023-01-19 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
150,000 +1.7%
5.30
US$794,925 		150,000 +1.7% 5.30 US$794,925
2022-12-28 2022-12-27 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
200,000 +2.3%
5.61
US$1,121,800 		200,000 +2.3% 5.61 US$1,121,800
2022-12-28 2022-12-23 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
200,000 +2.3%
5.88
US$1,176,800 		200,000 +2.3% 5.88 US$1,176,800
2022-11-25 2022-11-22 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
300,000 +3.6%
5.96
US$1,788,180 		300,000 +3.6% 5.96 US$1,788,180
2022-10-25 2022-10-24 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
250,000 +3.1%
4.36
US$1,090,500 		250,000 +3.1% 4.36 US$1,090,500
2022-10-25 2022-10-21 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
250,000 +3.2%
4.63
US$1,157,100 		250,000 +3.2% 4.63 US$1,157,100
2022-10-21 2022-10-20 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
285,977 +3.8%
4.00
US$1,143,565 		285,977 +3.8% 4.00 US$1,143,565
2022-10-21 2022-10-19 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
168,422 +2.3%
3.70
US$623,919 		168,422 +2.3% 3.70 US$623,919
2022-06-17 2022-06-15 B Purchase
3.3
Karrels James

SVP, CFO and Secretary

Officer
40,000 +26.4%
2.47
US$98,800 		40,000 +26.4% 2.47 US$98,800
2021-11-23 2021-11-19 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
200,000 +2.8%
18.50
US$3,700,320 		200,000 +2.8% 18.50 US$3,700,320
2021-07-20 2021-07-16 PlS Planned sale
Spitznagel Thomas

Sr VP, BPD & Manufacturing

Officer
5,000 -100.0%
25.01
US$125,050 		5,000 -100.0% 25.01 US$125,050
2021-06-17 2021-06-16 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
100,000 +1.6%
21.04
US$2,104,390 		100,000 +1.6% 21.04 US$2,104,390
2021-06-17 2021-06-15 B Purchase
2.4
BIOTECH TARGET N V
Large shareholder
75,000 +1.2%
20.53
US$1,539,615 		75,000 +1.2% 20.53 US$1,539,615
2021-04-19 2021-04-15 PlS Planned sale
Spitznagel Thomas

Sr VP, BPD & Manufacturing

Officer
5,000 -100.0%
30.91
US$154,550 		5,000 -100.0% 30.91 US$154,550
2021-03-24 2021-03-22 PlS Planned sale
3.3
Karrels James

SVP, CFO and Secretary

Officer
15,000 -9.5%
33.00
US$495,000 		15,000 -9.5% 33.00 US$495,000
2021-03-24 2021-03-22 PlS Planned sale
Bonvini Ezio

Sr VP, Research & CSO

Officer
3,917 -4.7%
32.00
US$125,344 		3,917 -4.7% 32.00 US$125,344
2021-03-09 2021-03-08 PlS Planned sale
Peters Jeffrey Stuart

General Counsel

Officer
21,749 -100.0%
26.50
US$576,348 		21,749 -100.0% 26.50 US$576,348
2020-12-30 2020-12-29 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
500 -1.1%
24.10
US$12,050 		500 -1.1% 24.10 US$12,050
2020-12-01 2020-11-30 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
500 -1.1%
23.35
US$11,675 		500 -1.1% 23.35 US$11,675
2020-10-29 2020-10-28 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
1,500 -3.3%
20.69
US$31,035 		1,500 -3.3% 20.69 US$31,035
2020-09-29 2020-09-28 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
500 -1.1%
25.33
US$12,665 		500 -1.1% 25.33 US$12,665
2020-09-21 2020-09-18 PlS Planned sale
Bonvini Ezio

Sr VP, Research & CSO

Officer
18,339 -18.0%
32.00
US$586,848 		18,339 -18.0% 32.00 US$586,848
2020-09-21 2020-09-17 PlS Planned sale
Bonvini Ezio

Sr VP, Research & CSO

Officer
44,512 -30.4%
29.88
US$1,330,019 		44,512 -30.4% 29.88 US$1,330,019
2020-09-10 2020-09-09 S Sale
3.2
Galbraith Kenneth
Non-Executive Director
6,924 -100.0%
27.11
US$187,710 		6,924 -100.0% 27.11 US$187,710
2020-09-10 2020-09-09 S Sale
3.2
Galbraith Kenneth
Non-Executive Director
13,849 -100.0%
27.11
US$375,446 		13,849 -100.0% 27.11 US$375,446
2020-08-27 2020-08-26 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
500 -1.1%
27.10
US$13,550 		500 -1.1% 27.10 US$13,550
2020-08-21 2020-08-20 PlS Planned sale
Spitznagel Thomas

Sr VP, BPD & Manufacturing

Officer
7,500 -100.0%
26.87
US$201,525 		7,500 -100.0% 26.87 US$201,525
2020-07-28 2020-07-27 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
3,000 -6.3%
25.63
US$76,890 		3,000 -6.3% 25.63 US$76,890
2020-07-28 2020-07-27 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
1,000 -2.1%
25.14
US$25,140 		1,000 -2.1% 25.14 US$25,140
2020-07-28 2020-07-27 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
489 -1.1%
25.13
US$12,289 		489 -1.1% 25.13 US$12,289
2020-07-06 2020-07-02 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
3,100 -6.5%
30.00
US$93,000 		3,100 -6.5% 30.00 US$93,000
2020-07-06 2020-07-02 PlS Planned sale
Peters Jeffrey Stuart

General Counsel

Officer
202 -100.0%
30.00
US$6,060 		202 -100.0% 30.00 US$6,060
2020-06-25 2020-06-24 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
500 -1.1%
28.49
US$14,245 		500 -1.1% 28.49 US$14,245
2020-05-27 2020-05-26 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
500 -1.1%
26.59
US$13,295 		500 -1.1% 26.59 US$13,295
2020-05-21 2020-05-20 PlS Planned sale
Spitznagel Thomas

Sr VP, BPD & Manufacturing

Officer
7,500 -100.0%
25.30
US$189,750 		7,500 -100.0% 25.30 US$189,750
2020-05-07 2020-05-06 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
3,532 -7.4%
25.00
US$88,300 		3,532 -7.4% 25.00 US$88,300
2020-05-07 2020-05-06 PlS Planned sale
Risser Eric Blasius

Sr VP & Chief Business Officer

Officer
3,000 -5.9%
20.00
US$60,000 		3,000 -5.9% 20.00 US$60,000
Explore more

More insider trading research around MacroGenics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America